Senores Pharmaceuticals Limited
Dec 20, 2024 - Dec 24, 2024
Senores Pharmaceuticals Limited IPO Details
Status
listed
Issue Price
₹372.00 - ₹391.00
Lot Size
38 Shares
Subscription
97.86 times
Listing Price
₹600 (53.45%)
Face Value
₹10 Per share
Issue Size
Approx ₹132.11 Cr
Fresh Issue
Approx ₹50 Cr
Total Shares Offered
Approx ₹82.11 Cr
Retail Quota
10%
QIB Quota
75%
HNI Quota
15%
Retail Approx
-
S-HNI Approx
-
B-HNI Approx
-
Issue Type
Book Built Issue IPO
Listing On
BSE, NSE
Registrar
Link Intime India Private Ltd
NSE Code
SENORES
BSE Code
544319
IPO Tentative Timetable
Valuation
Earning Per Share (EPS)
₹13.67
Price/Earning P/E Ratio
N/A
Return on Net Worth (RoNW)
23.60%
Net Asset Value (NAV)
₹66.96
Promoters
Pre issue Share Holding
71.10%
Post issue Share Holding
-
Company Promoters
- Swapnil Jatinbhai Shah
- Ashokkumar Vijaysinh Barot
Lead Managers
Equirus Capital Private Limited
Ambit Private Limited
Nuvama Wealth Management Limited
Live Subscription
| Date | QIB | NII | NII (> ₹10L) | NII (< ₹10L) | Retail | Total |
|---|---|---|---|---|---|---|
| Dec 20, 2024 | 0.01 | 1.77 | 1.13 | 3.15 | 7.9 | 1.94 |
| Dec 23, 2024 | 0.36 | 25.74 | 20.7 | 36.64 | 40.38 | 14.65 |
| Dec 24, 2024 | 97.84 | 100.35 | 95.25 | 111.35 | 93.16 | 97.86 |
Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 38 | ₹14,858 |
| Retail (Max) | 13 | 494 | ₹1,93,154 |
| S-HNI (Min) | 14 | 532 | ₹2,08,012 |
| S-HNI (Max) | 67 | 2,546 | ₹9,95,486 |
| B-HNI (Min) | 68 | 2,584 | ₹10,10,344 |
IPO Reservation
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | 66,65,725 (45%) | NA |
| QIB Shares Offered | 44,43,817 (30%) | NA |
| NII (HNI) Shares Offered | 22,21,909 (15%) | - |
| bNII > ₹10L | 15,18,605 (10.25%) | 2,854 |
| sNII < ₹10L | 7,03,304 (4.75%) | 1,322 |
| Retail Shares Offered | 14,81,272 (10%) | 38,980 |
| Total Shares Offered | 1,48,12,723 (100%) | - |
Company Financial
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 678.08 | 621.88 | 131.05 | 59.15 |
| Revenue | 183.35 | 217.34 | 39.02 | 14.63 |
| Profit After Tax | 23.94 | 32.71 | 8.43 | 0.99 |
| Net Worth | 319.06 | 231.71 | 45.5 | 36.59 |
| Reserves and Surplus | 263.36 | 175.94 | 35.25 | 25.37 |
| Total Borrowing | 242.03 | 248.38 | 60.76 | 14.21 |
About Company
The company offers various products, including:
- Tablets: Amphetamine Sulfate, Hydroxychloroquine Sulfate, Ketoconazole, Escitalopram, Irbesartan, Diclofenac Potassium, Morphine Sulfate, Methadone Hydrochloride, Prochlorperazine Maleate, and Cyclobenzaprine Hydrochloride.
- Capsules: Mexiletine Hydrochloride, Nicardipine Hydrochloride, Topiramate, Terazosin, and Butalbital/Acetaminophen/Caffeine.
- Specialty products: Ketorolac Tromethamine Tablets, Risperidone Tablets, and Ivermectin Tablets.
As of September 30, 2024, the company had launched 55 products across key therapeutic areas, including antibiotics and anti-fungal treatments. It has established partnerships with distributors and hospitals across several states in India.
The company operates a US FDA-approved manufacturing facility in Ahmedabad, Gujarat, ensuring high-quality production standards for regulated markets. It also has three dedicated research and development facilities in India and the US, focusing on innovation and developing differentiated products.
Senores Pharmaceuticals has a presence in 43 countries, supplying critical care injectables, active pharmaceutical ingredients (APIs), and specialty pharmaceutical products.
Its competitive strengths include expertise in regulated markets, a diverse portfolio of specialty and complex products, and long-term marketing agreements with pharmaceutical companies in the US, Canada, and the UK. The company also has a strong foothold in emerging markets with a tailored product portfolio, advanced R&D capabilities, and an experienced management team driving operational success.
Senores Pharmaceuticals continues to grow as a trusted provider of high-quality pharmaceutical solutions across therapeutic categories.
Company Contact
1101 to 1103, 11th floor,south tower, one 42 oppositejayantilal park,ambali bopal road, ahmedabad,-380054
Phone: +91-79-29999857
Email: cs@senorespharma.com
Website: https://senorespharma.com/
Registrar Contact
Phone: +91-22-4918 6270
Email: senorespharma.ipo@linkintime.co.in
Website: https://linkintime.co.in/initial_offer/public-issues.html